Anticonvulsant effects of bretazenil (Ro 16-6028) during ontogenesis
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články
- MeSH
- benzodiazepinony farmakologie MeSH
- dítě MeSH
- dospělí MeSH
- epilepsie chemicky indukované prevence a kontrola MeSH
- injekce intraperitoneální MeSH
- kindling MeSH
- krysa rodu Rattus růst a vývoj MeSH
- lidé MeSH
- pentylentetrazol * MeSH
- receptory GABA účinky léků MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- zvířata MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- krysa rodu Rattus růst a vývoj MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- benzodiazepinony MeSH
- bretazenil MeSH Prohlížeč
- pentylentetrazol * MeSH
- receptory GABA MeSH
Anticonvulsant action of a new benzodiazepine, bretazenil (Ro 16-6028), was studied in 240 rats in five age groups: age 7, 12, 18, 25 and 90 days. Motor seizures induced by metrazol (pentamethylenetetrazol, PTZ, 100 mg/kg subcutaneously (s.c.) except for 18-day-old rats which received a dose of 90 mg/kg) served as a model. Animals were pretreated with Ro 16-6028 in doses of 0.001-0.1 mg/kg intraperitoneally (i.p.) 10 min before metrazol. Both types of metrazol-induced seizures, minimal (mMS, predominantly clonic with preserved righting ability) and major (MMS, generalized tonic-clonic), were suppressed by Ro 16-6028 in a dose-dependent manner. Major seizures were always more sensitive to Ro 16-6028 than were minimal seizures. The youngest rats exhibited maximal effects of Ro 16-6028 against major seizures. On the other hand, this drug increased the incidence of minimal seizures in 7- and 12-day-old rats, i.e., in age groups in which this type of seizure is rare under control conditions.
Citace poskytuje Crossref.org
Epilepsy Research in the Institute of Physiology of the Czech Academy of Sciences in Prague
